Literature DB >> 3318890

Bisphosphonates--history and experimental basis.

H Fleisch1.   

Abstract

This paper reviews the mechanisms of action of the bisphosphonates, a new class of recently developed drugs. The geminal bisphosphonates are characterized by a P-C-P bond and are thus analogs of pyrophosphate. They bind strongly to hydroxyapatite crystals and in vitro inhibit both crystal formation and dissolution. In vivo, they inhibit soft tissue calcification and in some instances normal calcification. Furthermore, they are very potent inhibitors of bone resorption. The mechanism of action for the inhibition of calcification probably involves an inhibition of calcium phosphate crystal growth. However, the mode of action on bone resorption is not yet known, but is more likely to be cellular. The bisphosphonates are accumulated specifically in mineralized tissues. They are released when bone is resorbed so that osteoclasts and their precursors may be exposed to high local concentrations. Both inhibition of calcification and the effect on bone resorption is highly dependent upon the specific chemical structure of the individual bisphosphonate, so that each bisphosphonate must be considered as a compound per se. The only common characteristic is the tropism to mineral, which is due to the P-C-P group. This opens interesting possibilities for the development of new compounds.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318890

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  19 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.

Authors:  U Pedersen-Bjergaard; J Myhre
Journal:  BMJ       Date:  1991-02-02

3.  Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.

Authors:  S Fatemi; F R Singer; R K Rude
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

4.  Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo.

Authors:  G Golomb; A Schlossman; H Saadeh; M Levi; J M Van Gelder; E Breuer
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

5.  Comparative study of potential for bisphosphonates to damage gastric mucosa of rats.

Authors:  C P Peter; M V Kindt; J A Majka
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

6.  Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.

Authors:  A W Popp; R Senn; I Curkovic; C Senn; H Buffat; P F Popp; K Lippuner
Journal:  Osteoporos Int       Date:  2017-03-15       Impact factor: 4.507

7.  Effects of intracellular diphosphonates on cells of the mononuclear phagocyte system: in vivo effects of liposome-encapsulated diphosphonates on different macrophage subpopulations in the spleen.

Authors:  N van Rooijen; N Kors
Journal:  Calcif Tissue Int       Date:  1989-09       Impact factor: 4.333

8.  Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.

Authors:  A Sánchez; R Blanco
Journal:  Osteoporos Int       Date:  2016-11-20       Impact factor: 4.507

Review 9.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

10.  Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties.

Authors:  J A Guy; M Shea; C P Peter; R Morrissey; W C Hayes
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.